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Perioperative Management of the Patient with Diabetes Mellitus 
Topic 
Diabetes Mellitus 
• Diabetes Mellitus (DM) is “a group
of metabolic diseases characterized 
by hyperglycemia resulting from 
defects	 in insulin secretion, insulin
action or both”	 (McCance &
Huether, 2018, p. 789). 
• The American Diabetes Association 
(ADA)	 classifies diabetes mellitus 
into four categories: 
• Type I: beta-cell destruction
causing absolute insulin
deficiency 
• Type II: ranges from insulin 
resistance with insulin 
deficiency to insulin secretion
defect with insulin resistance 
• Other specific types 
• Gestational diabetes 
(McCance & Huether, 2018) 
• For the purpose of this poster, Type 
I	 & II	 will primarily be discussed. 
Why DM? 
• Diabetes mellitus is an	 extremely
prevalent co-morbidity in
hospitals around the globe. 
• In 	children, 1 	in 	300 	under 	the 
age	 of 12 can be	 diagnosed with
Type I Diabetes in the United
States (McCance & Huether,
2018). 
• In 	the 	U.S. 	it 	is 	estimated 	that 
approximately 10% of the	
population has diabetes mellitus
(Khan, et al., 2021). 
• According to the Center of
Disease Control and Prevention	 
[CDC]	 (2020), diabetes is the
seventh leading cause of death in
the United States. Additionally,
the medical cost	 of diabetes, along
with lost work	 wages, accounts
for 	$326 	billion 	per 	year 	in 	the 
U.S. (CDC, 2020). 
• “The American Diabetes 
Association conservatively
estimates that 25% of 
hospitalized adults have diabetes
mellitus, and that an estimated
25% to 50% of diabetic patients
will	 require surgery”	 (Nagelhout 
&	 Elisha, 2018, p. 800) 
• This topic was chosen because of
the prevalence of DM as a co-
morbidity and the need for
understanding of the condition as
an anesthesia	 provider. 
Underlying Signs & Symptoms 
• Type I diabetes generally presents Pathophysiology 
itself as wide fluctuations in blood • Type I DM “affects the metabolism of glucose, weight loss, polyuria, fat, protein and carbohydrates”	 polydipsia, fruity odor or breath, (McCance & Huether, 2018, p. 793). 
blurred vision and extreme fatigue • “It is caused by either a complete 
(Graney, 2019). lack of insulin production, an • Type I diabetics may present to the inadequate amount of insulin hospital with	 extremely high	 secreted	 by the beta cells	 of the glucose levels in diabetic pancreas, tissue insensitivity to 
ketoacidosis (DKA) (McCance & insulin, or insulin that is ineffective 
Huether, 2018). or destroyed before it can reach	 its • Signs and symptoms of DKA target site”	 (Cornelius, 2016, p. 208) include: extreme thirst and • As excess glucose accumulates in the increased urination (early), blood, it appears in the urine causing 
fast/deep 	breathing 	[Kussmal osmotic diuresis. Symptoms of 
breathing], dry skin and mouth, polydipsia and polyuria can be seen. flushed 	face, 	fruity-smelling breath, (McCance & Huether, 2018). headache, muscle-stiffness	 or • This also causes wide fluctuations in aches, being very tired, nausea	 and blood glucose levels, protein & fat 
vomiting and stomach pain breakdown resulting in weight loss 
(Diabetic Ketoacidosis,	 2021). (McCance & Huether, 2018). • Clinical	 manifestations of Type II • When glucose is not	 regulated with diabetes	 can be vague. The patient exogenous insulin in Type	 I patients, may be overweight, with extreme	 hyperglycemia	 can occur. 
dyslipidemia, elevated	 insulin This causes the ”release of free fatty 
levels, increased thirst &	 appetite, acids from adipocytes [and] sores	 that don’t heal and	 increases [the] production of ketone hypertension (McCance & Huether, bodies”	 (McCance & Huether, 2018, 2018). p. 793). Accumulation of these 
• Other signs and symptoms for ketone bodies leads to a drop in pH 
Type II Diabetes may include: and metabolic acidosis. This polyuria & polydipsia, fatigue, itchy condition is termed Diabetic	 skin (pruritis), recurrent Ketoacidosis (DKA) and can be life infections, changes in vision or threatening if left	 untreated 
neuropathy symptoms (McCance & (McCance & Huether, 2018). 
Huether, 2018). • DKA may be “the first sign of • Signs of hypoglycemia, or low diabetes	 in people who haven’t yet blood sugar, include tachycardia, been diagnosed”	 or caused by illness, shaking, sweating, nervousness	 or missing insulin shots, a clogged 
anxiety, irritability or confusion, insulin pump or wrong insulin dose 
dizziness	 or hunger (Low Blood (Diabetic Ketoacidosis,	 2021). Sugar (Hypoglycemia),	 2021) 
Figure 1. Pathophysiology	 of Type 2 Diabetes Mellitus. McCance & Huether, 2018, 
p. 795. 
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Significance of Pathophysiology 
• Obesity is a major component of • Severe disorders may occur in those 
Type 2 Diabetes, present with 60- whose diabetes has progressed 
80% of those diagnosed. Obesity without treatment. “Cardiovascular 
contributes to insulin resistance and atherosclerotic disease, including 
through adipokines (hormones cerebrovascular disease and ischemic	 
produced in adipose tissue), heart disease, is the major cause of 
elevated levels of free	 fatty acids, death in patients with type 2 diabetes”	 
cholesterol and triglycerides, as well (Cornelius, 2016, pp. 210-211). 
as inflammatory cytokines from
intra-abdominal adipocytes
(McCance & Huether, 2018). 
Figure 2. Multiorgan Causes and Consequences of Chronic Hyperglycemia in Type 
2	 Diabetes Mellitus. McCance & Huether, 2018, p. 795. 
Implications for Nursing Care 
• There are a plethora of risk factors associated with Type 2 Diabetes that nurses
should	 make patients	 aware of: 
• Non-modifiable risk factors include: family history, race or ethnic background
[diabetes is more prevalent in	 African-American, Asian-American, Latino-
Hispanic American, Native American or of Pacific-Islander 	descent], 		age 	[most 
frequent 	over 	age 	40] 	and 	gestational 	diabetes 	[those 	women 	with 	gestational
diabetes	 are more likely to develop diabetes	 later in life] (Diabetes	 Risk
Factors, 2021). 
• Modifiable Risk factors include: weight management, increasing physical
activity, blood pressure	 management, control of cholesterol/lipid levels,
smoking, diet, alcohol, stress	 management & sleep (Diabetes	 Risk Factors,
2021). 
• Type 2 Diabetes can be managed with lifestyle modifications, including diet and
exercise, and medications; however, Type	 1 diabetes requires lifelong exogenous
insulin (CDC, 2021). 
Diagnosis Treatment 
• Diagnosis can	 be made through 3 • Most instances require lifestyle 
tests: modifications [including physical 
• Hemoglobin A1C – can diagnose activity and a	 healthy diet] and 
prediabetes and diabetes medications to manage blood 
averaging a	 patient’s blood sugar glucose levels, cholesterol and blood 
over 2-3	 months. No fasting is pressure (Preventing and Treating 
required. An A1C of 5.7 – 6.4% Diabetes,	 2021). 
diagnoses	 prediabetes	 and	 • Most patients newly diagnosed with 
considers a person high risk	 for Type 2 Diabetes are started on 
diabetes. A person is	 diagnosed	 Metformin, a pill that helps decrease 
with diabetes when their A1C is the amount	 of glucose made in the 
6.5% or higher (Symptoms, liver (Preventing and Treating 
Diagnosis and Monitoring of	 Diabetes, 2021). 
Diabetes,	 2021). • Metformin may be taken in 
• The Fasting Plasma Glucose Test combination with subcutaneous 
requires a patient to not eat or	 insulin to help regulate blood 
drink (except water) for 8 hours	 glucose (Preventing and Treating 
prior to the test. A fasting blood Diabetes, 2021). 
glucose of 100-125mg/dL is • In 	Type 	I	Diabetes, 	the 	pancreas 
considered prediabetic	 and a does	 not produce any insulin so 
fasting 	blood 	glucose 	greater 	than subcutaneous	 insulin treatment will 
126	 mg/dL is considered diabetes be lifelong (Preventing and Treating 
mellitus (Symptoms, Diagnosis and Diabetes, 2021). 
Monitoring of	 Diabetes,	 2021). • Insulin 	varies 	in 	dose 	and 	how 
• The final test is the Oral Glucose quickly it works. A doctor may 
Tolerance Test which examines prescribe rapid-acting insulin 
how well your body handles a (working within 15 minutes after 
certain amount of glucose. The injection and peak time in 1-2	 hours 
healthcare provider draws blood 1 and continues to work for 2-4hrs), 
hour prior and 2 hours after regular	 or	 short-acting insulin 
receiving a large premeasured (bloodstream within 30 minutes of 
beverage containing glucose. A injection, peaks 2-3hrs after 
glucose measurement of 140- injection and continues to work 3-
199mg/dL is considered 6hrs after injection), intermediate-
prediabetes and a glucose of acting insulin (hits the	 bloodstream 
200mg/dL is considered diabetes within 2-4hrs after injection, peaks 
mellitus (Symptoms, Diagnosis and 12hrs after injection and continues 
Monitoring of	 Diabetes,	 2021). to work for 12-18hrs) or long-acting 
• Once diagnosed, patients are given insulin (reaches the bloodstream 
an at home	 blood glucose	 monitor several hours	 after injection and	 can 
to allow them to check their blood stabilize blood	 glucose levels	 for 
sugar throughout the day approximately 24hrs) (Preventing 
(Symptoms, Diagnosis and and Treating Diabetes, 2021).. 
Monitoring of	 Diabetes,	 2021). • Patients may also be prescribed 
• Diabetes cannot be cured but medications to prevent heart disease 
treatment	 is available. or stroke, manage high	 blood
pressure or cholesterol medication. 
Perioperative Considerations 
• Careful	 preoperative history and physical	 examination should be completed to
minimize any surgical risks to the patient as well as preoperative labs,
primarily blood sugar testing (Khan et al., 2021). 
• Goals throughout surgery should include “avoidance of hypoglycemia,
prevention of ketoacidosis, maintenance of fluid and electrolyte balance, and
avoidance of marked hyperglycemia”	 (Khan et al., 2021). 
• Prandial insulin (regular, lispro, aspart,	 and glulisine)	 should be stopped when
patient is NPO for surgery to avoid hypoglycemia (Khan et al., 2021). 
• Medical professionals should be aware that surgery and general anesthesia can
cause a neuroendocrine stress response with release of counter regulatory
hormones causing insulin resistance, increased lipolysis and hyperglycemia
(Khan et al., 2021). 
Perioperative 
Considerations Cont. 
• Lastly, providers should be
aware	 that signs and
symptoms	 of hyper- or 
hypoglycemia can be masked 
with general anesthesia and
sedation (Khan et al., 2021). 
• For short procedures, blood
glucose should be checked
preoperative and immediately 
postoperative. For long
surgeries, blood	 sugar should	
be checked every 1-2	 hours
(Khan et al., 2021). 
Conclusions 
• Diabetes is an	 extremely
prevalent co-morbidity seen
outpatient and inpatient by
advanced nursing providers. 
• This disorder can be modified by
lifestyle changes with Type 2
Diabetes but requires life-long
exogenous insulin with Type	 1
Diabetes. 
• Without	 treatment,
hyperglycemia can cause several
multiorgan system	 consequences
(McCance & Huether, 2018) 
• Signs and symptoms of hyper-
and hypoglycemia	 may be	 hidden
during surgery, so it is	 important
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FIGURE 22-14 Multiorgan Causes and Common Consequences of Chronic Hyperglycemia in Type 2 Diabetes 
Mellitus.lL,lnterleukin;PVD,Peripheralvasculardisease;TNF,Tumornecrosisfactor. 
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